Suven Life Sciences Ltd (Suven) announced that it has secured product patents in Australia, Eurasia, Israel and USA to its new chemical entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2032, 2030, 2031 and 2032 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

With these new patents, Suven has a total of twenty four granted patents from Australia, seventeen granted patents from Eurasia, nine granted patents from Israel and twenty four granted patents from USA. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” says Venkat Jasti, CEO of Suven.

“Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a phase 2 undergoing candidate SUVN-502, phase 1 completed candidate SUVN-G3031 and phase 1 undergoing candidate SUVN-D4010 for Alzheimer’s disease and schizophrenia. In addition to that the company has ten internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.